Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s
Digest more
Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations ...
The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review ...
The new, higher dose of Wegovy (semaglutide 7.2 mg) is currently under review with the European Medicines Agency, in the U.K., and several other countries. In the EU, Novo Nordisk expects a ...
While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.
And one of them is pharmaceutical giant Pfizer ( PFE +1.98%). Now, with a major step along the path to entering this ...
Novo Nordisk is filing its supplemental new drug application (sNDA) for Wegovy 7.2 mg on the back of the phase 3b STEP UP ...
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...
Through the FDA’s priority voucher program, Novo Nordisk said Nov. 26 it has filed an application seeking approval of its Wegovy 7.2 milligram injection. Wegovy (semaglutide) is currently approved in ...
Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback